Precision Bb Targeting, Robust Efficacy, Transfusion Independence, Excellent Safety in Phase II PNH Study, and Subcutaneous Administration The 12-16-week open-label study evaluated Ruxoprubart as ...
ViiV Healthcare has reported several successful HIV trials at CROI 2026, including its investigational candidates lotivibart, ...
ViiV Healthcare presents data for two investigational HIV treatment therapies with potential for twice-yearly dosing: London Saturday, February 28, 2026, 13:00 Hrs [IST] ViiV Heal ...
AI can be a powerful tool for productivity, but risks come with its rewards.
It's designed to take the place of complicated, multiple drug regimens that many people with HIV need to follow. And it's ...
Vaccinations for measles and other diseases have served us well for decades — maybe so well that we’ve forgotten how bad things can be without them.
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today ...
Approval based on unprecedented Phase 3 data demonstrating statistically significant improvements in progression-free survival and overall survival versus standard of care regimens83.3% of ...
An average of one baby a week in the Southern Health region is being given a preventive treatment after a potential measles ...
Is your employer among the largest or smallest gender pay gaps? More than 5.9 million workers from over 10,000 employers can now see the data for themselves.
Despite her past insistence that she wouldn't go under the knife, side-by-side photos of Melania Trump have many netizens ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results